Zydus Lifesciences and Sunshine Healthcare Lanka have formed a joint venture aimed at creating a pharmaceutical manufacturing facility in Sri Lanka, with an investment of $20 million. This initiative marks an important milestone in enhancing the country’s capacity for local drug production.

The foundational work for this new plant commenced on June 26, with the ceremony taking place in the Board of Investment (BOI) Zone located in Horana. The facility is planned to cover an area of approximately four acres and will focus primarily on producing pharmaceutical products for the local retail market in Sri Lanka.

This project is part of Sri Lanka’s ongoing efforts to encourage domestic manufacturing in essential sectors, aiming to reduce dependence on imports and improve access to high-quality healthcare products.

Strategic Partnership Benefits

The collaboration between Zydus and Sunshine Healthcare combines Zydus Lifesciences’ proficiency in pharmaceutical manufacturing with Sunshine Healthcare Lankan’s well-established distribution network. This partnership aims to enhance local production capabilities and facilitate the transfer of technology, thereby bolstering the pharmaceutical industry within Sri Lanka.

In addition to increasing the production of domestic medicines, the new facility is expected to create job opportunities for the local workforce, contributing positively to the long-term growth of Sri Lanka’s healthcare sector. The establishment of this plant demonstrates a commitment from both companies to improve healthcare accessibility while also supporting industrial development through advanced pharmaceutical processes.

This joint venture is in alignment with Sri Lanka’s broader initiatives to boost healthcare security by expanding domestic production capabilities. By reducing reliance on imported medicines, the country aims to enhance its pharmaceutical landscape.

Future Implications for Healthcare in Sri Lanka

The facility’s establishment is not merely a financial investment but a strategic move to uplift the standards of healthcare in Sri Lanka. By fostering local production, the joint venture seeks to reinforce the self-sufficiency of the country’s healthcare system, allowing it to respond more effectively to the needs of its citizens.

The partners have also expressed their dedication to ensuring that the new plant adheres to international quality standards. This commitment is expected to place the facility among the leaders in pharmaceutical manufacturing within the region, catering not just to local but potentially export markets in the future.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share